Inspire Medical Systems Earnings Preview
As Inspire Medical Systems is set to reveal its quarterly earnings, excitement is building among investors. The company, known for its innovative medical technology, is expected to release its earnings on August 4, 2025.
Analysts are predicting that Inspire Medical Systems will announce an earnings per share (EPS) of $0.21. Investors are keenly watching to see if the company can meet or exceed this benchmark while providing positive guidance for the upcoming quarter.
Understanding Earnings Reactions
New investors should be aware that while the actual earnings figures are significant, the market's reaction often hinges more on the company's guidance moving forward. Last quarter, Inspire Medical Systems impressed by beating its EPS expectations by $0.33, which resulted in a 1.98% surge in its stock price the following day.
Examining Past Earnings Performance
Here’s a general overview of Inspire Medical Systems's previous earnings performance:
Quarterly Performance Snapshot:
- Q1 2025: EPS Estimate: -$0.23, Actual: $0.10, Price Change: 2.0%
- Q4 2024: EPS Estimate: $0.71, Actual: $1.15, Price Change: 2.0%
- Q3 2024: EPS Estimate: $0.08, Actual: $0.60, Price Change: 3.0%
- Q2 2024: EPS Estimate: -$0.15, Actual: $0.32, Price Change: 28.00%
Current Stock Performance
As of July 31, shares of Inspire Medical Systems were trading at $124.54, showing a decline of 14.12% over the past year. With investors feeling the pinch from these downturns, there is a mix of hope and trepidation going into this earnings announcement.
Analyst Insights on Inspire Medical Systems
It's essential for investors to understand the latest market sentiments regarding Inspire Medical Systems. Notably, analysts have rated the company with a consensus rating of Outperform based on a total of six ratings. The average price target over the next year is projected at $197.33, suggesting potential growth of approximately 58.45%.
Comparison with Industry Peers
In analyzing the landscape, comparisons with industry peers such as Integer Holdings, TransMedics Group, and Envista Holdings provide valuable insights. Here’s a snapshot of their anticipated performance:
- Integer Holdings: Rating: Buy, Price Target: $138.0 (10.81% upside)
- TransMedics Group: Rating: Outperform, Price Target: $135.83 (9.07% upside)
- Envista Holdings: Rating: Neutral, Price Target: $20.75 (83.34% downside)
Benchmarking Peers
Below is a summary of key metrics for each of the companies compared:
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| Inspire Medical Systems | Outperform | 22.75% | $170.61M | 0.45% |
| Integer Holdings | Buy | 11.36% | $129.15M | 2.24% |
| TransMedics Group | Outperform | 37.68% | $96.59M | 11.95% |
| Envista Holdings | Neutral | -1.07% | $336M | 0.60% |
Inspire Medical Systems Background
Inspire Medical Systems Inc specializes in medical technology, focusing on innovative solutions for patients suffering from obstructive sleep apnea (OSA). Their flagship Inspire system utilizes neurostimulation technology to provide an effective treatment for moderate to severe cases of OSA. The company's business model primarily operates within the United States and Europe, contributing significantly to its revenue growth.
Financial Insights
Market Capitalization: The company's market capitalization sits below industry averages due to various factors affecting its growth prospects.
Revenue Growth: In recent months, Inspire Medical Systems has displayed impressive progress, marking a revenue growth of 22.75%, indicating a strong upward trend in earnings.
Net Margin: The company exhibits a net margin of 1.49%, showcasing its profitable operations and effective cost management.
Return on Equity (ROE): Inspire Medical Systems has demonstrated a commendable ROE of 0.45%, reflecting its effectiveness in utilizing equity capital.
Return on Assets (ROA): With an ROA of 0.39%, the company highlights its ability to effectively utilize assets for enhanced returns.
Debt Management: Taking a conservative approach, Inspire maintains a debt-to-equity ratio of 0.05, showing disciplined financial management.
Frequently Asked Questions
What is Inspire Medical Systems known for?
Inspire Medical Systems specializes in creating minimally invasive solutions for patients with obstructive sleep apnea, promoting innovative treatments.
What is the expected EPS for Inspire Medical Systems?
Analysts anticipate an EPS of $0.21 for their upcoming earnings report.
How have the stock shares performed recently?
The stock has experienced a 14.12% decline over the past year, trading at $124.54 as of July 31.
What are the analyst ratings for Inspire Medical Systems?
Inspire Medical Systems has a consensus rating of Outperform from analysts, with a price target of $197.33.
What is the company’s revenue growth?
Inspire Medical Systems reported a revenue growth of 22.75% in recent months, indicating a positive trend.
